Campanelli Named to Slayback Board of Directors
1 March 2021 - - US-based specialty pharmaceutical company Slayback Pharma LLC has appointed Paul Campanelli to its board of directors, the company said.

Campanelli is the chairman of Endo Pharmaceuticals, and was, until recently, president and CEO of Endo Pharmaceuticals, where he led a turnaround focused on executing Endo's strategy to improve productivity, simplify their business, and increase the value of the company's US Branded, US Generics and international pharmaceutical assets.

He transformed the company through investments in high-barrier, technically challenging generic products and specialty brands--all with a laser focus on differentiated and intelligent product selection.

Earlier, Campanelli served as chief executive officer of Par Pharmaceutical Companies, Inc. following the company's September 2012 acquisition by TPG.

While CEO of Par, Campanelli built a strong leadership team and an industry-leading specialty pharmaceutical business with a diverse portfolio of complex generics and 505(b)2s. 

Under Campanelli's direction, Par entered the sterile injectables segment via the JHP acquisition, positioning the company for future growth. 

Notably, Par's sterile injectable segment ultimately grew from a baseline of zero to over USD 1bn in revenue during Paul's tenure at Par and Endo. 

Campanelli's success in growing Par culminated in the acquisition of Par by Endo in 2015 for over USD 8bn.

Prior to Campanelli's tenure as Par's CEO, he served as COO and president of Par Pharmaceutical, Inc., the company's generics division.

Prior to joining Par, Campanelli served as vice president, Business Development at Dr. Reddy's Laboratories Ltd.

Slayback is a New-Jersey based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.